Bimekizumab: all 49 studies that test it

Page 1 of 1. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.

• Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of BimekizumabNot yet recruitingNCT07836283Phase 3
• Efficacy of Bimekizumab in Adults With Pyoderma GangrenosumNot yet recruitingNCT07767864Phase 2
• Bimzelx (Bimekizumab) For The Treatment Of Adult Onset Pityriasis Rubra Pilaris (PRP)Not yet recruitingNCT07497620Phase 4
• Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingNCT07352566Phase 4
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar PustulosisRecruitingNCT07219420Phase 3
• Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingNCT07138898Phase 2
• A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)RecruitingNCT06888193Phase 1
• Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?RecruitingNCT06742333Phase 2
• An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic ArthritisRecruitingNCT06668181Phase 3
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque PsoriasisCompletedNCT06011733Phase 3Results posted
• A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study ParticipantsCompletedNCT05292131Phase 1Results posted
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque PsoriasisCompletedNCT05020249Phase 3Results posted
• A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque PsoriasisCompletedNCT04718896Phase 2Results posted
• A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study ParticipantsTerminatedNCT04255862Phase 1Results posted
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT04242498Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT04242446Phase 3Results posted
• A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic ArthritisCompletedNCT04109976Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing SpondylitisCompletedNCT03928743Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial SpondyloarthritisCompletedNCT03928704Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisCompletedNCT03896581Phase 3Results posted
• A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisCompletedNCT03895203Phase 3Results posted
• A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)CompletedNCT03766685Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT03598790Phase 3Results posted
• A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT03410992Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT03370133Phase 3Results posted
• A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing SpondylitisCompletedNCT03355573Phase 2Results posted
• A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic ArthritisCompletedNCT03347110Phase 2Results posted
• A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.CompletedNCT03248531Phase 2Results posted
• A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque PsoriasisCompletedNCT03230292Phase 2Results posted
• A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing SpondylitisCompletedNCT03215277Phase 2Results posted
• A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque PsoriasisCompletedNCT03025542Phase 2Results posted
• A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque PsoriasisCompletedNCT03010527Phase 2Results posted
• A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory ArthritisCompletedNCT02969525Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing SpondylitisCompletedNCT02963506Phase 2Results posted
• Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque PsoriasisCompletedNCT02905006Phase 2Results posted
• A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingNCT06921850Phase 3
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic ArthritisCompletedNCT06624228Phase 3
• A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque PsoriasisActive, not recruitingNCT06506916Phase 3
• Bimekizumab in Plaque PsoriasisCompletedNCT06336343Phase 4
• Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic ArthritisWithdrawnNCT05499416Phase 4
• A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy SubjectsCompletedNCT05028127Phase 1
• A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT04901195Phase 3
• A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisCompletedNCT04436640Phase 3
• Dose Reduction of IL17 and IL23 Inhibitors in PsoriasisCompletedNCT04340076Phase 4
• A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisCompletedNCT04009499Phase 3
• A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy SubjectsCompletedNCT03895385Phase 1
• A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer ParticipantsCompletedNCT03707717Phase 1
• A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With PsoriasisCompletedNCT02529956Phase 1
• Multiple Dose Study of UCB4940 in Subjects With Psoriatic ArthritisCompletedNCT02141763Phase 1

← Bimekizumab overview